Long-term survival in patients with acute leukemia and chronic disseminated Candidiasis despite minimal antileukemic therapy

Haematologica

Volumn 91, Issue 10, 2006, Pages 1422-1423

  Karthaus, Meinolf ^a,b   Hebart, Holger ^c   Einsele, Hermann ^c   Schaefer, Hansjoerg ^c   Scheel Walter, Hans ^c,f   Buchheidt, Dieter ^d,e   Lehrnbecher, Thomas ^g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Pediatric Hematology and Oncology   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g Medizinische Klinik ^*

Author keywords

Acute leukemia; Chronic disseminated candidiasis; Immunobiology

Indexed keywords

ANTILEUKEMIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; MITOXANTRONE; PREDNISONE; TIOGUANINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CANDIDIASIS; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HUMAN; IMMUNE RESPONSE; KIDNEY INFECTION; LONG TERM CARE; LUNG INFECTION; MALE; PRESCHOOL CHILD; SIDE EFFECT; SPLEEN DISEASE;

ADULT; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CANDIDIASIS; CHILD, PRESCHOOL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SURVIVORS;

EID: 33750017261     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) 2004;18:9-14.
2. Ribeiro P, Sousa AB, Nunes O, Aveiro F, Fernandes JP, Gouveia J. Candidemia in acute leukemia patients. Support Care Cancer 1997;5:249-51.
3. Anttila VJ, Elonen E, Nordling S, Sivonen A, Ruutu T, Ruutu P. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 1997;24:375-80.
4. Karthaus M, Huebner G, Geissler RG, Heil G, Ganser A. Hepatic lesions of chronic disseminated systemic candidiasis in leukemia patients may become visible during neutropenia: value of serial ultrasound examinations. Blood 1998;91:3087-9.
5. Sallah S, Semelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P. Hepatosplenic candidiasis in patients with acute leukaemia. Br J Haematol 1999;106:697-701.
6. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:2357-62.
7. Wade JC, Gaffey M, Wiemik PH, Schimpff SC, Schiffer CA, Wesley M et al. Hepatitis in patients with acute nonlymphocytic leukemia. Am J Med 1983;75:413-22.
8. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004;4:1-23.
9. Romani L. Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr Opin Microbiol 1999;2:363-7.
10. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of Candida albicans: augmentation by granulocyte colony-stimulating factor and interferon-gamma. J Infect Dis 1992;166:668-73.
11. Roilides E, Katsifa H, Tsaparidou S, Stergiopoulou T, Panteliadis C, Walsh TJ. Interleukin 10 suppresses phagocytic and antihyphal activities of human neutrophils. Cytokine 2000;12:379-87.
12. Vonk AG, Netea MG, van Krieken JH, Iwakura Y, van der Meer JW, Kullberg BJ. Endogenous interleukin (IL)-1α and IL-1β are crucial for host defense against disseminated candidiasis. J Infect Dis 2006;193:1419-26.
13. Stuyt RJ, Netea MG, van Krieken JH, van der Meer JW, Kullberg BJ. Recombinant interleukin-18 protects against disseminated Candida albicans infection in mice. J Infect Dis 2004;189:1524-7.
14. + T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun 1996;64:4907-14.
15. Long GS, Hiserodt JC, Hamaha JB, Cramer DV. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Transplantation 1988;46:433-8.
16. Herrera C, Garcia-Perez MJ, Ramirez R, Martin C, Alvarez MA, Martinez F et al. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 1997;19:545-51.
17. + effector T cells mediate indirect interleukin-12- and interferon-γ-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2002;62:2611-7.
18. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.